Foundation Pasqual Maragall Advances in Alzheimer’s Treatment with New Pharmaceutical Development
In a significant milestone for medical research and treatment, the Foundation Pasqual Maragall, a renowned institution dedicated to the study and treatment of Alzheimer's disease, has made a groundbreaking announcement regarding the commercialization of a new pharmaceutical product aimed at combating this debilitating condition.
The Context of Alzheimer’s Research
Alzheimer's disease, a progressive neurological disorder, has been a focal point of extensive research globally. In Spain, particularly in Catalonia, institutions like the Barcelonaβeta Brain Research Center have been at the forefront of innovative studies. Recently, a study by this center led to the approval of a new biomarker for measuring amyloid plaques, a hallmark of Alzheimer’s, by the European Medicines Agency (EMA)[4].
Read more ->